United Health Products, Inc.

Evaluation of Disclosure Controls and Procedures

The Company is in the process of implementing disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ‘‘Exchange Act’’), that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer and Principal Financial Officer to allow timely decisions regarding required disclosure.

Effective on June 12, 2025, the Company’s officer holding the Vice President of Finance and Principal Financial Officer positions resigned, citing consideration of personal and professional factors. The Company is seeking and will consider suitable replacement candidates to replace this officer in these positions. In the interim, United Health Products’ Chief Executive Officer, Brian Thom, is acting as the Company’s principal financial officer.

As of September 30, 2025, the Chief Executive Officer and Principal Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedures and concluded that the Company’s disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2025, there were no changes in our system of internal controls over financial reporting.